<DOC>
	<DOC>NCT01356498</DOC>
	<brief_summary>This is an open-label extension phase of two double-blind, placebo-controled Phase 3 protocols evaluating PEG-uricase in the treatment of hyperuricemic subjects with symptomatic gout. The purpose of this study is to provide a continuation of treatment to subjects completing the double-blind studies and obtain long-term safety and efficacy data.</brief_summary>
	<brief_title>Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout</brief_title>
	<detailed_description />
	<mesh_term>Gout</mesh_term>
	<criteria>Completed treatment in one of two doubleblind, placebo controlled studies of PEGuricase in subjects with hyperuricemia and symptomatic gout unstable angina uncontrolled arrhythmia uncontrolled hypertension end stage renal disease requiring dialysis anemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>gout</keyword>
	<keyword>chronic gout</keyword>
</DOC>